Thiazolidinediones and associated risk of bladder cancer: A systematic review and meta-analysis

British Journal of Clinical Pharmacology

Volumn 78, Issue 2, 2014, Pages 258-273

  Turner, Richard M ^a,b   Kwok, Chun S ^c   Chen Turner, Chen ^b   Maduakor, Chinedu A ^c   Singh, Sonal ^d   Loke, Yoon K ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

diabetes mellitus; meta analysis; pioglitazone; rosiglitazone; thiazolidinedione; urinary bladder neoplasm

Indexed keywords

PIOGLITAZONE; ROSIGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE;

ARTICLE; BLADDER CANCER; CANCER RISK; DRUG EXPOSURE; DRUG USE; EMBASE; HUMAN; MEDLINE; META ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; TREATMENT DURATION; BLADDER TUMOR; CHEMICALLY INDUCED; DOSE RESPONSE; RISK; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RISK; THIAZOLIDINEDIONES; URINARY BLADDER NEOPLASMS;

EID: 84902603532     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12306     Document Type: Article

References (62)

1. Burger M, Catto JWF, Dalbagni G, Grossman HB, Herr H, Karakiewicz P, Kassouf W, Kiemeney LA, La Vecchia C, Shariat S, Lotan Y,. Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 2013; 63: 234-241.
2. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Altekruse SF, Kosary CL, Ruhl J, Tatolovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA,. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute, 2011. Available at http://seer.cancer.gov/csr/1975-2009-pops09/ (last accessed 2 October 2013).
3. Bortolini M, Wright MB, Bopst M, Balas B,. Examining the safety of PPAR agonists-current trends and future prospects. Expert Opin Drug Saf 2013; 12: 65-79.
4. European Medicines Agency. Actos: European public assessment report-Product Information. 2012. Available at http://www.ema.europa.eu/ema/ index.jsp?curl=pages/medicines/human/medicines/000285/human-med-000624. jsp&murl=menus/medicines/medicines.jsp&mid=WC0b01ac058001d124 (last accessed 12 October 2013).
5. Assessment report for Actos, Glustin, Competact, Glubrava, Tandemact. 2011. Available at http://www.ema.europa.eu/docs/en-GB/document-library/EPAR- Assessment-Report-Variation/human/000285/WC500126656.pdf (last accessed 12 October 2013).
6. El Hage J,. Toxicity profile of peroxisome proliferator activated receptor (PPAR) agonists and preclinical safety profile for muraglitazar. 2005. Available at http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4169S2-02-02- FDA-ElHage.ppt (last accessed 12 October 2013).
7. Lubet RA, Fischer SM, Steele VE, Juliana MM, Desmond R, Grubbs CJ,. Rosiglitazone, a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl) nitrosamine-induced urinary bladder cancers. Int J Cancer 2008; 123: 2254-2259.
8. Cohen SM,. Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci 2005; 87: 322-327.
9. Suzuki S, Arnold LL, Pennington KL, Kakiuchi-Kiyota S, Wei M, Wanibuchi H, Cohen SM,. Effects of pioglitazone, a peroxisome proliferator-activated receptor gamma agonist, on the urine and urothelium of the rat. Toxicol Sci 2010; 113: 349-357.
10. Sato K, Awasaki Y, Kandori H, Tanakamaru Z-Y, Nagai H, Baron D, Yamamoto M,. Suppressive effects of acid-forming diet against the tumorigenic potential of pioglitazone hydrochloride in the urinary bladder of male rats. Toxicol Appl Pharmacol 2011; 251: 234-244.
11. Hillaire-Buys D, Faillie J-L, Montastruc J-L, Petit P,. Stay vigilant: a glitazone (pioglitazone) can hide a glitazar! Eur J Clin Pharmacol 2012; 68: 1681-1683.
12. Press announcements-FDA significantly restricts access to the diabetes drug Avandia. 2010. [cited 2013 Oct 12]. Available at http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm226975.htm (last accessed 12 October 2013).
13. European Medicines Agency-news and events-European Medicines Agency recommends suspension of Avandia, Avandamet and Avaglim. 2010. [cited 12 Oct 2013]. Available at http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and- events/news/2010/09/news-detail-001119.jsp&mid=WC0b01ac058004d5c1 (last accessed 12 October 2013).
14. Graham DJ, Ouellet-Hellstrom R, MaCurdy TE, Ali F, Sholley C, Worrall C, Kelman JA,. Risk of acute myocardial infarction, stroke, heart failure, and death in elderly Medicare patients treated with rosiglitazone or pioglitazone. JAMA 2010; 304: 411-418.
15. Food and Drug Administration. FDA drug safety communication: ongoing safety review of Actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. 2010. Available at http://www.fda.gov/Drugs/ DrugSafety/ucm226214.htm (last accessed 12 October 2013).
16. Food and Drug Administration. FDA drug safety communication: updated drug labels for pioglitazone-containing medicines. 2011. Available at http://www.fda.gov/Drugs/DrugSafety/ucm266555.htm (last accessed 12 October 2013).
17. European Medicines Agency Committee for Medicinal Products for Human Use. Questions and answers on the review of pioglitazone-containing medicines (Actos, Glustin, Competact, Glubrava and Tandemact). 2011. Available at http://www.ema.europa.eu/docs/en-GB/document-library/Medicine-QA/2011/07/ WC500109179.pdf (last accessed 12 October 2013).
18. European Medicines Agency. European Medicines Agency recommends new contra-indications and warnings for pioglitazone to reduce small increased risk of bladder cancer. 2011. Available at http://www.ema.europa.eu/ema/index.jsp? curl=pages/news-and-events/news/2011/07/news-detail-001311.jsp&mid= WC0b01ac058004d5cl (last accessed 12 October 2013).
19. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, Allemand H,. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study. Diabetologia 2012; 55: 1953-1962.
20. Colmers IN, Bowker SL, Majumdar SR, Johnson JA,. Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. CMAJ 2012; 184: E675-683.
21. Zhu Z, Shen Z, Lu Y, Zhong S, Xu C,. Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract 2012; 98: 159-163.
22. Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH,. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med 2013; 30: 1026-1032.
23. Bhaumik S,. Flip flop policy over pioglitazone licence causes media storm in India. BMJ 2013; 347: f4937-f4937.
24. Tucker ME,. FDA panel advises easing restrictions on rosiglitazone. BMJ 2013; 346: f3769-f3769.
25. Glaxo SmithKline. Results summaries: rosiglitazone. n.d. Available at http://www.gsk-clinicalstudyregister.com/result-comp-list.jsp;jsessionid= 25A02DE6B0E4CF1857C249D6EBF3250C?compound=rosiglitazone&studyType= All&phase=All&population=All&marketing=All (last accessed 16 October 2012).
26. US National Institutes of Health. ClinicalTrials.gov registry. n.d. Available at http://www.clinicaltrials.gov (last accessed 16 October 2012).
27. Loke YK, Price D, Herxheimer A,. Chapter 14: adverse effects. In: Cochrane Handbook for Systematic Reviews of Interventions, eds, Higgins JPT, Green S,. Chichester: John Wiley & Sons, 2008; 433-448.
28. Ioannidis JPA, Trikalinos TA,. The appropriateness of asymmetry tests for publication bias in meta-analyses: a large survey. CMAJ 2007; 176: 1091-1096.
29. Bradburn MJ, Deeks JJ, Berlin JA, Russell Localio A,. Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events. Stat Med 2007; 26: 53-77.
30. Davies HT, Crombie IK, Tavakoli M,. When can odds ratios mislead? BMJ 1998; 316: 989-991.
31. Deeks JJ, Higgins JP, Altman DG,. Chapter 9: analysing data and undertaking meta-analyses. In: Cochrane Handbook for Systematic Reviews of Interventions, eds, Higgins JPT, Green S,. Chichester: John Wiley & Sons, 2008; 243-296.
32. Cates C,. Dr Chris Cates EBM web site. 2008. Available at http://www.nntonline.net/visualrx/ (last accessed 2 October 2013).
33. Dormandy JA, Charbonnel B, Eckland DJA, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefèbvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Korányi L, Laakso M, Mokán M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Schernthaner G, Schmitz O, Skrha J, Smith U, Taton J,. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-1289.
34. Dormandy J, Bhattacharya M, van Troostenburg de Bruyn A-R,. Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive. Drug Saf 2009; 32: 187-202.
35. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM,. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA 2008; 299: 1561-1573.
36. Takeda Global Research & Development Center Inc. Efficacy study of pioglitazone compared to glimepiride on coronary atherosclerotic disease progression in subjects with type 2 diabetes mellitus (PERISCOPE). 2012 Update. Available at http://clinicaltrials.gov/ct2/show/NCT00225277 (last accessed 2 October 2013).
37. Tolman KG, Freston JW, Kupfer S, Perez A,. Liver safety in patients with type 2 diabetes treated with pioglitazone: results from a 3-year, randomized, comparator-controlled study in the US. Drug Saf 2009; 32: 787-800.
38. Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJV,. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet 2009; 373: 2125-2135.
39. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G,. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
40. Home PD, Kahn SE, Jones NP, Noronha D, Beck-Nielsen H, Viberti G,. Experience of malignancies with oral glucose-lowering drugs in the randomised controlled ADOPT (A Diabetes Outcome Progression Trial) and RECORD (Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of Glycaemia in Diabetes) clinical trials. Diabetologia 2010; 53: 1838-1845.
41. Lewis JD, Ferrara A, Peng T, Hedderson M, Bilker WB, Quesenberry CP Jr, Vaughn DJ, Nessel L, Selby J, Strom BL,. Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. Diabetes Care 2011; 34: 916-922.
42. Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD,. Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study. J Natl Cancer Inst 2012; 104: 1411-1421.
43. Tseng C-H,. Diabetes and risk of bladder cancer: a study using the National Health Insurance database in Taiwan. Diabetologia 2011; 54: 2009-2015.
44. Tseng C-H,. Pioglitazone and bladder cancer: a population-based study of Taiwanese. Diabetes Care 2012; 35: 278-280.
45. Wei L, Macdonald TM, Mackenzie IS,. Pioglitazone and bladder cancer: a propensity score matched cohort study. Br J Clin Pharmacol 2013; 75: 254-259.
46. Azoulay L, Yin H, Filion KB, Assayag J, Majdan A, Pollak MN, Suissa S,. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012; 344: e3645.
47. Chang C-H, Lin J-W, Wu L-C, Lai M-S, Chuang L-M, Chan KA,. Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus. Hepatology 2012; 55: 1462-1472.
48. Piccinni C, Motola D, Marchesini G, Poluzzi E,. Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting. Diabetes Care 2011; 34: 1369-1371.
49. Fujimoto K, Hamamoto Y, Honjo S, Kawasaki Y, Mori K, Tatsuoka H, Matsuoka A, Wada Y, Ikeda H, Fujikawa J, Koshiyama H,. Possible link of pioglitazone with bladder cancer in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2013; 99: e21-23.
50. Tseng C-H,. Rosiglitazone is not associated with an increased risk of bladder cancer. Cancer Epidemiol 2013; 37: 385-389.
51. Hsiao F-Y, Hsieh P-H, Huang W-F, Tsai Y-W, Gau C-S,. Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone: a nested case-control study. Drug Saf 2013; 36: 643-649.
52. Song SO, Kim KJ, Lee B-W, Kang ES, Cha BS, Lee HC,. The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. Diabetes Metab J 2012; 36: 371-378.
53. De Boer A,. When to publish measures of disproportionality derived from spontaneous reporting databases? Br J Clin Pharmacol 2011; 72: 909-911.
54. Loke YK, Singh S, Furberg CD,. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ 2009; 180: 32-39.
55. Lincoff AM, Wolski K, Nicholls SJ, Nissen SE,. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007; 298: 1180-1188.
56. Faillie J-L, Petit P, Montastruc J-L, Hillaire-Buys D,. Scientific evidence and controversies about pioglitazone and bladder cancer: which lessons can be drawn? Drug Saf 2013; 36: 693-707.
57. Sinha B, Ghosal S,. Pioglitazone-do we really need it to manage type 2 diabetes? Diabetes Metab Syndr 2013; 7: 52-55.
58. Long GG, Reynolds VL, Lopez-Martinez A, Ryan TE, White SL, Eldridge SR,. Urothelial carcinogenesis in the urinary bladder of rats treated with naveglitazar, a gamma-dominant PPAR alpha/gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol Pathol 2008; 36: 218-231.
59. Long GG, Reynolds VL, Dochterman LW, Ryan TE,. Neoplastic and non-neoplastic changes in F-344 rats treated with Naveglitazar, a gamma-dominant PPAR alpha/gamma agonist. Toxicol Pathol 2009; 37: 741-753.
60. Hillaire-Buys D, Faillie J-L, Montastruc J-L,. Pioglitazone and bladder cancer. Lancet 2011; 378: 1543-1544.
61. Singh S,. Replies to Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis. 2012. Available at http://www.cmaj.ca/content/184/12/E675.short/reply#cmaj-el-712534 (last accessed 23 November 2012).
62. Jacobs BL, Lee CT, Montie JE,. Bladder cancer in 2010: how far have we come? CA Cancer J Clin 2010; 60: 244-272.